EKF – EKF Diagnostics Holdings plc

EKF Diagnostics (LSE:EKF) gave investors a familiar message on 30 July 2026, but with a sharper edge on profitability. In an unaudited trading update covering the six months to 30 June 2026, the AIM-listed diagnostics and life sciences group reported that revenue held broadly flat at £25.0m while its gross margin widened to 53%, up from 50% in the same period a year earlier. The Cardiff-based company also pointed to a stronger balance sheet, with cash rising to £16.0m and no bank borrowings, and reaffirmed that it expects to grow both revenue and adjusted EBITDA over the full year in line with market expectations.

The significance of the update lies less in the top line, which barely moved, than in the quality of the earnings underneath it. EKF has spent the past three years simplifying its product range, shedding lower-margin lines and tightening cost control, and the latest figures suggest that discipline is still feeding through to margins and cash generation even when headline sales are static.

Company background

EKF Diagnostics (LSE:EKF) operates in two broad areas. Its Point-of-Care division supplies rapid, near-patient testing devices and consumables, spanning haemoglobin and anaemia screening, HbA1c and glucose testing for diabetes, and lactate measurement. Its Life Sciences arm manufactures enzymes and reagents, is a significant global supplier of beta-hydroxybutyrate (β-HB), and runs a growing contract fermentation and manufacturing operation.

The group is led by executive chairman Julian Baines, a long-standing figure in the UK diagnostics sector, with Steve Young as chief financial officer. Since suspending its dividend, EKF has returned capital to shareholders through buybacks, and it is now working through a five-year strategic plan first outlined in March 2025 that aims to build Life Sciences into a world-class contract development and manufacturing organisation while expanding haematology market access.

What the update showed

The standout operational feature of the first half was Life Sciences, where revenues rose 20% year on year. Within that, β-HB sales grew 4% and, more notably, contract manufacturing performed particularly well as EKF continued to build out its fermentation and CDMO pipeline. The Point-of-Care side was steadier: management said diabetes and haematology delivered solid performances, with the bulk of the year's high-volume tenders already won and scheduled for delivery in the historically stronger second half.

That phasing matters. EKF's business is seasonally weighted, and the company framed the flat first-half revenue as consistent with a back-end-loaded year rather than a sign of stalling demand. The margin improvement, meanwhile, reflects a richer mix and the cumulative effect of earlier portfolio pruning.

The financials in detail

Revenue of £25.0m compared with £25.2m in the first half of 2025, effectively flat. The gross margin of 53% extends a clear multi-year trend: the same measure was around 48% in the first half of 2024 and 50% a year ago. Management said adjusted EBITDA showed continued growth, though it did not attach a specific figure to the interim number.

On cash, EKF reported £16.0m at 30 June 2026, up from £15.8m of net cash at the end of December 2025, and confirmed it carried no bank debt. Within that balance, cash held in its Russian subsidiary and effectively restricted rose to £2.4m from £2.1m, leaving unrestricted operational cash somewhat lower than the headline. During the half the company deployed roughly £0.9m of a £1.4m buyback allocation, continuing the return-of-capital policy that saw about £5.0m handed back over the 2025 financial year.

Comparison with earlier periods

The trajectory is easier to read against the audited 2025 results published on 24 March 2026. For the full year to December 2025, EKF reported revenue of £51.6m, up 2.8%, a gross margin of 51%, and adjusted EBITDA of £12.4m, up 9.3%. Point-of-Care contributed £33.0m and Life Sciences £17.9m, with haematology and diabetes both advancing and β-HB up more than 10%.

Set against that backdrop, the first-half margin of 53% represents further progress, and the reaffirmed guidance implies management still expects 2026 to build on 2025 rather than mark time. The pattern of flat-to-modest revenue growth paired with expanding margins has become the defining characteristic of the post-restructuring EKF.

Strategy and growth drivers

The clearest growth engine is Life Sciences. EKF's ambition to develop a genuine contract development and manufacturing capability, anchored by its fermentation assets, gives it exposure to structurally growing demand for outsourced biomanufacturing. The 20% first-half growth and the expanding contract pipeline are early evidence that this pivot is gaining traction.

On the Point-of-Care side, the strategy leans on deeper penetration of existing markets rather than new-product fireworks: greater instrument placements pulling through higher-margin consumables, expansion in US blood banking, and haematology-led anaemia screening programmes in Africa. On our reading, the investment case rests on this combination of a steady, cash-generative diagnostics base funding a higher-growth life sciences opportunity.

Industry and competitive context

EKF competes in a crowded in-vitro diagnostics market dominated by far larger players such as Abbott, Roche and Siemens Healthineers, so its strategy is deliberately niche-led, focusing on segments where it can hold defensible positions. In contract manufacturing and fermentation it faces a different peer set of specialist CDMOs, an area where scale, capacity utilisation and validation credentials are decisive. As a sub-£120m company, EKF is a minnow in both arenas, which makes execution and margin discipline more important to it than sheer volume.

Risks and uncertainties

Several caveats temper the improving margin story. Revenue has been essentially flat for consecutive halves, so the earnings quality is doing much of the work; a sustained top-line stall would eventually cap EBITDA growth. The reliance on a strong second half to hit full-year targets introduces execution and timing risk around tender deliveries.

The Russian cash position, which grew again to £2.4m and remains difficult to repatriate, is a persistent overhang and a reminder of geopolitical exposure. Currency movements have flattered and hurt the reported figures in recent periods. And with the dividend suspended and the shares trading on a full earnings multiple, the equity story depends on delivery of the five-year plan rather than income.

Milestones to watch

The next hard data point is the full interim report, expected in September, which should quantify adjusted EBITDA and confirm the cash and margin figures flagged in the update. Beyond that, investors will look for evidence that the seasonally stronger second half converts the won tenders into revenue, for continued momentum in contract fermentation, and for any progress on unlocking the trapped Russian cash. The pace and size of further buybacks will also signal management's confidence.

Conclusion

EKF's first-half update was, on balance, a reassuring one: margins are still climbing, cash is building, the balance sheet is debt-free, and Life Sciences is growing at a double-digit clip. Against that, revenue remains stubbornly flat and much of the year's delivery is deferred to the second half, so the full-year outcome is not yet locked in. For a company that has rebuilt its profitability through discipline rather than growth, the coming interim results and the second-half tender deliveries will show whether the improving margin trend can finally be paired with a moving top line.